StreetInsider.com News Articles

Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results

Thu, 20 Aug 2026 09:20:30 -0400

(Updated - August 20, 2026 9:20 AM EDT)

Benchmark analyst Bruce Jackson raised the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $15.00 (from $13.00) while maintaining a Speculative Buy rating.

The analyst commented, "We are updating our model for 2Q results. Recall that on June 30 Unicycive received a second Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) for oxylanthanum carbonate (OLC), and once again the rejection is related to a deficiency at a third-party manufacturing vendor employed by its CDMO. The company noted that it is in active and ongoing discussion with the FDA regarding

Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results

Thu, 20 Aug 2026 09:20:30 -0400

(Updated - August 20, 2026 9:20 AM EDT)

Benchmark analyst Bruce Jackson raised the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $15.00 (from $13.00) while maintaining a Speculative Buy rating.

Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260814/26932055.html

Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260814/26932055.html

Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930860.html

Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930860.html

Unicycive Therapeutics (UNCY) PT Lowered to $20 at B.Riley

Thu, 13 Aug 2026 08:59:54 -0400

B.Riley lowered its price target on Unicycive Therapeutics (NASDAQ: UNCY) to $20.00 (from $22.00) while maintaining a Buy rating.

Unicycive Therapeutics (UNCY) PT Lowered to $25 at Guggenheim

Thu, 13 Aug 2026 06:48:20 -0400

(Updated - August 13, 2026 6:48 AM EDT)

Guggenheim analyst Vamil Divan lowered the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $25.00 (from $37.00) while maintaining a Buy rating.

The analyst commented: "Unicycive released 2Q 2026 results and provided a corporate update earlier today. Unfortunately, the wait continues for the FDA to inspect the subcontractor manufacturing site that is responsible for the company receiving a second Complete Response Letter for oxylanthanum carbonate (OLC) on June 29th. We spoke to management this morning, and they said they have been in close contact with the FDA on the issue and continue to believe

Unicycive Therapeutics (UNCY) PT Lowered to $25 at Guggenheim

Thu, 13 Aug 2026 06:48:20 -0400

(Updated - August 13, 2026 6:48 AM EDT)

Guggenheim analyst Vamil Divan lowered the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $25.00 (from $37.00) while maintaining a Buy rating.

Form 8-K Unicycive Therapeutics, For: Aug 12

Wed, 12 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26909256.html

Form 8-K Unicycive Therapeutics, For: Aug 12

Wed, 12 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26909256.html

Unicycive Therapeutics, Inc (UNCY) Tops Q2 EPS by 42c

Wed, 12 Aug 2026 07:35:20 -0400

Unicycive Therapeutics, Inc (NASDAQ: UNCY) reported Q2 EPS of ($0.06), $0.42 better than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Unicycive Therapeutics, Inc (UNCY) click here.

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 07:19:00 -0400